Drug-Induced Orthostatic Hypotension in UK Primary Care: A Self-Controlled Case Series Study
Abstract
Background: Drug-induced orthostatic hypotension (OH) is common and increasing worldwide with rising polypharmacy. Real-world evidence is crucial for safe prescribing. We examined the risk of OH associated with commonly prescribed drugs in UK primary care among adults aged ≥60 years.
Methods: This was a self-controlled case series using routinely collected UK primary care data from the IQVIA Medical Research Database (IMRD). Individuals with an OH diagnosis and drug exposure between 1 January 2000 and 31 December 2018 were included. Drug classes potentially causing OH were coded by British National Formulary sub-chapters. Incidence rate ratios (IRRs) of OH were compared across a 90-day pre-exposure period and three post-prescription risk periods (day 1-28; day 29-56; day 57+) against periods outside these risk periods (reference period).
Results: Of 2,597,077 eligible individuals, 41,005 (1.6%) had a first-recorded OH diagnosis; 51% were women. Increased OH risk was associated with initiation of all cardiovascular system (CVS), central nervous system (CNS), and urinary retention drugs, and some anti-diabetic drugs. Across most classes, OH risk peaked sharply after initiation (day 1-28) and then declined. Drugs causing OH via sympathetic inhibition, diuresis, or mixed mechanisms had the highest risk (eg, uroselective alpha-blockers: IRR 4.94, 95% CI 4.38-5.58) during day 1-28. Vasodilation-causing drugs had lower risk (eg, calcium-channel blockers: IRR 1.88, 95% CI…
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health. Reported size: 2,597,077 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.